Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471194 | 0.86 | CA1 (0.54) | LMNACA12CA1CA2CA7 | |
| SCHEMBL14577677 | 0.85 | SLC7A5 (0.46) | LMNACA12CA1CA2CA7 | |
| SCHEMBL3488840 | 0.81 | CA12 (0.46) | LMNACA12CA1CA2CA7 | |
| SCHEMBL14577792 | 0.80 | KDM4E (0.40) | LMNACA12CA1CA2CA7 | |
| SCHEMBL14577653 | 0.80 | SLC7A5 (0.49) | LMNACA12CA1CA2CA7 | |
| SCHEMBL20888449 | 0.79 | CA12 (0.47) | LMNACA12CA1CA2CA7 | |
| SCHEMBL3554201 | 0.78 | CA1 (0.48) | LMNACA12CA1CA2CA7 | |
| SCHEMBL584301 | 0.78 | CA12 (0.46) | LMNACA12CA1CA2CA7 | |
| SCHEMBL16396395 | 0.78 | NOTUM (0.54) | LMNACA12CA1CA2CA7 | |
| SCHEMBL12852570 | 0.77 | KDM4E (0.49) | LMNACA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | ALKAHEST, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105314-A1 | Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | LMNA 632/4885CA12 4246/4885CA1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.